---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-000115"
form_type: "8-K"
ticker: "GNLX"
cik: "0001231457"
company_name: "GENELUX Corp"
filed_at: "2026-01-02T23:59:59+00:00"
generated_at: "2026-05-16T11:47:07.863727+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Genelux appoints Jason Litten as CMO after Paul Scigalla resigns

## Summary
- Paul Scigalla, M.D., resigned as CMO effective December 30, 2025.
- Jason Litten, M.D., appointed CMO effective January 2, 2026; previously CMO at Chimeric Therapeutics.
- Dr. Litten receives base salary of $475,000/year, 40% target bonus, and option to purchase 275,000 shares vesting over 4 years.
- Severance: 6 months salary (non-CIC) or 12 months (CIC) plus COBRA coverage.

## SEC filing metadata
- accession: 0001493152-26-000115
- form_type: 8-K
- ticker: GNLX
- cik: 0001231457
- company_name: GENELUX Corp
- filed_at: 2026-01-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1231457/000149315226000115/0001493152-26-000115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1231457/000149315226000115/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-000115
- JSON: https://secwatch.observer/filing/0001493152-26-000115.json
- Plain text: https://secwatch.observer/filing/0001493152-26-000115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.